Genotypes of catechol-O-methyltransferase and response to levodopa treatment in patients with Parkinson's disease

Neuroscience Letters

Volumn 298, Issue 2, 2001, Pages 131-134

  Lee, Myung Sik ^a   Lyoo, Chul Hyoung ^a   Ulmanen, Ismo ^b   Syvänen, Ann Christine ^c   O Rinne, Juha ^d  

^a Yonsei University College of Medicine   (South Korea)

^b NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^c UPPSALA UNIVERSITY   (Sweden)

^d TURKU PET CENTRE   (Finland)

Author keywords

Catechol O methyltransferase; Levodopa test; Minisequencing; Multiple system atrophy; Parkinson's disease; Polymorphism

Indexed keywords

ADENINE; CARBIDOPA PLUS LEVODOPA; CATECHOL METHYLTRANSFERASE; GUANINE; NUCLEOTIDE;

ADULT; AGED; ALLELE; ARTICLE; CONTROLLED STUDY; DRUG RESPONSE; ENZYME ACTIVITY; FEMALE; GENE FREQUENCY; GENOTYPE; HUMAN; KOREA; MAJOR CLINICAL STUDY; MALE; PARKINSON DISEASE; PRIORITY JOURNAL; PROVOCATION TEST; RATING SCALE; SHY DRAGER SYNDROME; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; AGED; ANTIPARKINSON AGENTS; CATECHOL O-METHYLTRANSFERASE; FEMALE; GENOTYPE; HUMANS; KOREA; LEVODOPA; MALE; MIDDLE AGED; MULTIPLE SYSTEM ATROPHY; PARKINSON DISEASE; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 0035793491     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3940(00)01749-3     Document Type: Article

References (22)

1. The relationship between COMT genotype and the clinical effectiveness of tolcapone, a COMT inhibitor, in patients with Parkinson's disease
2. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease
3. Chromosomal mapping of the human catechol-O-methyltransferase gene to 22q11.1-q11.2
4. Catecholamine metabolism: basic aspects and clinical significance
5. High and low activity alleles of catechol-O-methyltransferase gene: ethnic difference and possible association with Parkinson's disease
6. Tolcapone fluctuator study group I. Tolcapone improves motor function and reduces levodopa requirement in patients with Parkinson's disease experiencing motor fluctuations: a multicenter, double blind randomized, placebo-controlled trial
7. Ethnic differences in catechol O-methyltranferase pharmacogenetics: frequency of ther codon 108/158 low activity allele is lower in Kenyan than Caucasian or South-west Asian individuals
8. Characteristics of catechol-O-methyltransferase (COMT) and properties of selective COMT inhibitors
9. Pharmacokinetics and pharmacodynamics of levodopa: clinical implications
10. Effect of peripheral catechol-O-methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients
11. Multiple system atrophy
12. Catechol-O-methyltransferase activity: a determinant of levodopa response
13. COMT inhibition with entacapone in the treatment of Parkinson's disease
14. COMT inhibition in the treatment of Parkinson's disease
15. Difference in erythrocyte catechol-O-methyltransferase activity between Orientals and Caucasians: difference in levodopa tolerance
16. Determination of catechol-O-methyltransferase activity in relation to melanin metabolism using high performance liquid chromatography with fluorimetric detection
17. Genetic polymorphism of catechol-O-methyltransferase (COMT): correlation of genotype with individual variation of S-COMT activity and comparison of the allele frequencies in the normal population and parkinsonian patients in Finland
18. Variability and validity of polymorphism association studies in Parkinson's disease
19. Epidemiology of Parkinson's disease
20. Clinical features and natural history of multiple system atrophy. An analysis of 100 cases
21. G/A1947 polymorphism in catechol-O-methyltransferase (COMT) gene in Parkinson's disease
22. Catechol-O-methyltransferase genotype and susceptibility to Parkinson's disease in Japan